Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Molecular Templates, Inc. MTEM
$0.42
+$0 (0.69%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
23791646.00000000
-
week52high
1.38
-
week52low
0.31
-
Revenue
19754000
-
P/E TTM
0
-
Beta
1.37439400
-
EPS
-1.65000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:30
Описание компании
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B of A Securities | Underperform | Buy | 27 мая 2022 г. |
| Barclays | Overweight | Overweight | 30 мар 2022 г. |
| B of A Securities | Buy | 21 апр 2021 г. | |
| UBS | Neutral | 01 февр 2021 г. | |
| Jefferies | Buy | 08 сент 2020 г. | |
| Barclays | Overweight | Overweight | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kim Jason S. | D | 0 | 12089 | 07 июл 2022 г. |
| Kim Jason S. | A | 95493 | 12089 | 07 июл 2022 г. |
| McLennan Sean | A | 30000 | 30000 | 16 июн 2022 г. |
| LALANDE KEVIN M. | A | 222000 | 62000 | 15 июн 2022 г. |
| SHV Management Services, LLC | A | 222000 | 62000 | 15 июн 2022 г. |
| LALANDE KEVIN M. | A | 160000 | 60000 | 14 июн 2022 г. |
| SHV Management Services, LLC | A | 160000 | 60000 | 14 июн 2022 г. |
| LALANDE KEVIN M. | A | 100000 | 100000 | 13 июн 2022 г. |
| SHV Management Services, LLC | A | 100000 | 100000 | 13 июн 2022 г. |
| Sanders Corazon (Corsee) D. | A | 15000 | 15000 | 03 июн 2022 г. |
Новостная лента
9 Hot Penny Stocks Under $0.99 To Watch Right Now
PennyStocks
05 апр 2023 г. в 11:48
Penny stocks to watch under $1 The post 9 Hot Penny Stocks Under $0.99 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
30 мар 2023 г. в 21:40
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is Molecular Templates (MTEM) Stock Up 36% Today?
InvestorPlace
10 мар 2023 г. в 08:01
Molecular Templates (NASDAQ: MTEM ) stock is rocketing higher on Friday after the company got approval from the FDA. That FDA approval has to do with its IND application for its cancer treatment.
Molecular Templates Announces Participation in Upcoming Conferences
GlobeNewsWire
01 мар 2023 г. в 16:44
AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, announced participation in the following upcoming 2023 conferences:
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire
02 дек 2022 г. в 17:02
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium (SABCS) which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX. Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 – December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. In-person and virtual meetings may be scheduled directly with Molecular Templates.